These treatments are effective in the
early stage of diabetic nephropathy [1,2], but are
hardly effective in the advanced stage when there is an
increase in serum creatinine. On the other hand,
angiotensin converting enzyme inhibitor (ACE-I) [3–
7] and angiotensin receptor antagonist (ARB) [8–10]
have been reported to reduce the progression of
diabetic nephropathy to some extent